Key result
Various drugs, vaccines, and alternative strategies have shown potential to prevent or combat Coxsackievirus B infections in vitro and in vivo.
Why the study?
Coxsackieviruses B cause diseases ranging from mild symptoms to severe conditions like cardiomyopathy and type 1 diabetes, but developing safe and effective strategies to combat them remains challenging.
This review highlights the diverse therapeutic strategies currently in development, including antivirals and vaccines, to combat coxsackievirus B infections and prevent severe complications like cardiomyopathy.
Preclinical findings for Coxsackievirus B therapies should not yet change practice; human trials needed to confirm efficacy.
Coxsackieviruses B (CVB) are small, non-enveloped, single-stranded RNA viruses belonging to the Enterovirus genus of the Picornaviridae family. They are common worldwide and cause a wide variety of human diseases ranging from those having relatively mild symptoms to severe acute and chronic pathologies such as cardiomyopathy and type 1 diabetes. The development of safe and effective strategies to combat these viruses remains a challenge. The present review outlines current approaches to control CVB infections and associated diseases. Various drugs targeting viral or host proteins involved in viral replication as well as vaccines have been developed and shown potential to prevent or combat CVB infections in vitro and in vivo in animal models. Repurposed drugs and alternative strategies targeting miRNAs or based on plant extracts and probiotics and their derivatives have also shown antiviral effects against CVB. In addition, clinical trials with vaccines and drugs are underway and offer hope for the prevention or treatment of CVB-induced diseases.
No takes yet. Share an insight, caveat, or question.
Alhazmi et al. (2022) conducted a review in Coxsackievirus B infections. Antiviral strategies (drugs, vaccines, alternative therapies) was evaluated. Various drugs, vaccines, and alternative strategies have shown potential to prevent or combat Coxsackievirus B infections in vitro and in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: